Research programme: protein therapies - CureVac

Drug Profile

Research programme: protein therapies - CureVac

Alternative Names: Protein replacement therapy - CureVac; RNAntibody®; RNArt®protein therapy; Sequence engineered mRNA - CureVac

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator CureVac
  • Developer Acuitas Therapeutics; CureVac
  • Class Proteins
  • Mechanism of Action Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Rabies; Unspecified

Most Recent Events

  • 08 Nov 2016 CureVac has patent protection for RNAntibody® technology in Europe
  • 08 Nov 2016 Preclinical trials in Cancer in Germany (Parenteral) before November 2016
  • 08 Nov 2016 Preclinical trials in Rabies (Prevention) in Germany (Parenteral) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top